Addressing the Challenges of Treating Moderate to Severe Atopic Dermatitis With Targeted Biologic Therapies in Pediatric Patients

This activity includes patient counseling video vignettes.

Program Description

Moderate to severe atopic dermatitis (AD) in children significantly impacts their quality of life, as well as that of their caregivers. Managing moderate to severe pediatric AD can present challenges due to concerns about medication safety and adherence. Biologic therapies offer a promising new approach for pediatric AD as they target specific inflammatory pathways, with safety and efficacy pointing towards their potential role in overcoming limitations of traditional therapies. Specialty pharmacists can support the use of biologics for pediatric patients with AD by providing education, monitoring for adverse effects, and ensuring medication adherence. This session features case-based video vignettes that will examine treatment challenges in pediatric AD and assist specialty pharmacists in sharing counseling pearls and navigating strategies to ensure the optimal use of biologics in the management of pediatric AD.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: July 24, 2024
Expiration date: July 24, 2025

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the substantial disease burden of moderate to severe atopic dermatitis (AD) for pediatric patients and caregivers
• Examine approved and emerging biologic therapies used to manage moderate to severe AD in children, considering safety and efficacy data
• Identify opportunities for pharmacists to aid pediatric patients and caregivers in the management of moderate to severe AD through improved utilization of biologic therapies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-24-226-H01-P. The activity is available for CE credit through July 24, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Alyssa Wu, PharmD, BCPPS, AE-C

Damien R.T. Fisher, PharmD, AE-C

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms